How would you approach treatment for a postmenopausal patient who was treated more than 5 years ago with AC-T for TNBC, and who now presents with ipsilateral, locally advanced, node-positive TNBC, but has severe residual neuropathy from prior taxane exposure?  

Standard neoadjuvant chemotherapy for TNBC would have been anthracycline- and taxane-based regimens, with the addition of platinum agents (carboplatin or cisplatin) in high-risk cases to improve pathologic complete response (pCR) rates. However, in this case further taxane use (including docetaxel) ...